<p>在最新的季度中，5 位分析師對 OrthoPediatrics（NASDAQ: KIDS）提供了評級，展現出看漲和看跌的不同觀點。</p>
<p>下表提供了他們最近評級的快速概覽，突顯出過去 30 天情緒的變化，並與前幾個月進行比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師評估的 12 個月價格目標揭示了進一步的見解，平均目標為 24.2 美元，最高估計為 30.00 美元，最低估計為 20.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的 22.67 美元的平均價格目標增加了 6.75%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772460030_0_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772460030_0_0.png"/></p>
<h2>解讀分析師評級：深入分析</h2>
<p>通過對最近分析師行動的深入探索，揭示了 OrthoPediatrics 在金融專家中的地位。以下摘要概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上調</td>
<td>持有</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>上調</td>
<td>買入</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>上調</td>
<td>買入</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>宣佈</td>
<td>買入</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>宣佈</td>
<td>買入</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，反映了他們對 OrthoPediatrics 近期發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 分析師對股票進行定性評估，範圍從 “跑贏大盤” 到 “跑輸大盤”。這些評級傳達了分析師對 OrthoPediatrics 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師預測價格目標的變動，提供對 OrthoPediatrics 未來價值的估計。檢查當前和之前的目標提供了分析師不斷變化的預期的見解。</li>
</ul>
<p>理解這些分析師評估與關鍵財務指標的關係，可以為 OrthoPediatrics 的市場地位提供有價值的見解。保持信息靈通，做出經過深思熟慮的決策，參考我們的評級表。</p>
<p>隨時瞭解 OrthoPediatrics 的分析師評級。</p>
<p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
<h2>發現 OrthoPediatrics：更深入的觀察</h2>
<p>OrthoPediatrics Corp 是一家醫療設備公司。該公司致力於為兒科骨科市場提供產品。該公司設計、開發和商業化植入物和儀器，以滿足外科醫生和患者的需求。其產品包括 PediLoc、PediPlates、空心螺釘、PediFlexTM 釘、PediNailTM、PediLoc 脛骨和 ACL 重建系統等。</p>
<h3>深入瞭解 OrthoPediatrics 的財務狀況</h3>
<p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相較於同行規模較小。這一定位可能受到感知增長潛力或運營規模等因素的影響。</p>
<p><strong>收入增長：</strong> 在過去的 3 個月中，OrthoPediatrics 表現積極，截至 2025 年 9 月 30 日實現了 <strong>12.23%</strong> 的收入增長率。這反映了公司營業收入的顯著增加。與醫療保健行業的其他公司相比，該公司的增長率高於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> OrthoPediatrics 的淨利潤率低於行業標準，表明在實現強勁盈利能力方面存在困難。淨利潤率為 <strong>-19.22%</strong>，公司可能在有效控制成本方面面臨挑戰。</p>
<p><strong>股本回報率（ROE）：</strong> OrthoPediatrics 的 ROE 低於行業平均水平，表明在最大化股本回報方面存在挑戰。ROE 為 <strong>-3.34%</strong>，公司可能在實現最佳財務表現方面面臨障礙。</p>
<p><strong>資產回報率（ROA）：</strong> OrthoPediatrics 的 ROA 低於行業標準，表明在有效利用資產方面存在困難。ROA 為 <strong>-2.36%</strong>，公司可能在從其資產中獲得令人滿意的回報方面面臨挑戰。</p>
<p><strong>債務管理：</strong> OrthoPediatrics 的債務與股本比率低於行業平均水平。比率為 <strong>0.28</strong>，公司較少依賴債務融資，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
<h2>理解分析師評級的相關性</h2>
<p>評級來自分析師，或在銀行和金融系統內的專家，他們為特定股票或定義的行業報告（通常每季度一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以做出決策。</p>
<p>分析師可以通過納入增長預估、收益和收入等指標的預測來增強他們的評估，為投資者提供額外的指導。重要的是要承認，儘管分析師在股票和行業方面是專家，但他們也是人，在提供見解時會表達自己的觀點。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

KIDS

<p>在最新的季度中，5 位分析師對 OrthoPediatrics（NASDAQ:KIDS）給出了混合評級，平均 12 個月目標價為 24.2 美元，較之前的目標價上漲了 6.75%。分析師們提高了他們的評級，其中 Truist Securities 和 Needham 等公司的升級尤為顯著。儘管公司收入增長率為 12.23%，但面臨着-19.22% 的淨利潤率和-3.34% 的股本回報率（ROE）等挑戰。OrthoPediatrics 維持了 0.28 的較低債務與股本比率，表明其在債務和股本之間保持了更健康的平衡。分析師評級為公司在市場上的地位和未來預期提供了洞察</p>

<p>In the latest quarter, 5 analysts provided ratings for OrthoPediatrics (NASDAQ: KIDS), showcasing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最新的季度中，5 位分析師對 OrthoPediatrics（NASDAQ: KIDS）提供了評級，展現出看漲和看跌的不同觀點。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的快速概覽，突顯出過去 30 天情緒的變化，並與前幾個月進行比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.2, a high estimate of $30.00, and a low estimate of $20.00. This upward trend is evident, with the current average reflecting a 6.75% increase from the previous average price target of $22.67.</p>
<div class="lb-trans"><p>分析師評估的 12 個月價格目標揭示了進一步的見解，平均目標為 24.2 美元，最高估計為 30.00 美元，最低估計為 20.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的 22.67 美元的平均價格目標增加了 6.75%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772460030_0_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1772460030_0_0.png"/></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<div class="lb-trans"><h2>解讀分析師評級：深入分析</h2>
</div><p>The standing of OrthoPediatrics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過對最近分析師行動的深入探索，揭示了 OrthoPediatrics 在金融專家中的地位。以下摘要概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上調</td>
<td>持有</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>上調</td>
<td>買入</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>上調</td>
<td>買入</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>宣佈</td>
<td>買入</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>宣佈</td>
<td>買入</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OrthoPediatrics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for OrthoPediatrics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，反映了他們對 OrthoPediatrics 近期發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 分析師對股票進行定性評估，範圍從 “跑贏大盤” 到 “跑輸大盤”。這些評級傳達了分析師對 OrthoPediatrics 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師預測價格目標的變動，提供對 OrthoPediatrics 未來價值的估計。檢查當前和之前的目標提供了分析師不斷變化的預期的見解。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into OrthoPediatrics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解這些分析師評估與關鍵財務指標的關係，可以為 OrthoPediatrics 的市場地位提供有價值的見解。保持信息靈通，做出經過深思熟慮的決策，參考我們的評級表。</p>
</div><p>Stay up to date on OrthoPediatrics analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 OrthoPediatrics 的分析師評級。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
</div><h2>Discovering OrthoPediatrics: A Closer Look</h2>
<div class="lb-trans"><h2>發現 OrthoPediatrics：更深入的觀察</h2>
</div><p>OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.</p>
<div class="lb-trans"><p>OrthoPediatrics Corp 是一家醫療設備公司。該公司致力於為兒科骨科市場提供產品。該公司設計、開發和商業化植入物和儀器，以滿足外科醫生和患者的需求。其產品包括 PediLoc、PediPlates、空心螺釘、PediFlexTM 釘、PediNailTM、PediLoc 脛骨和 ACL 重建系統等。</p>
</div><h3>A Deep Dive into OrthoPediatrics's Financials</h3>
<div class="lb-trans"><h3>深入瞭解 OrthoPediatrics 的財務狀況</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相較於同行規模較小。這一定位可能受到感知增長潛力或運營規模等因素的影響。</p>
</div><p><strong>Revenue Growth:</strong> Over the 3M period, OrthoPediatrics showcased positive performance, achieving a revenue growth rate of <strong>12.23%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> 在過去的 3 個月中，OrthoPediatrics 表現積極，截至 2025 年 9 月 30 日實現了 <strong>12.23%</strong> 的收入增長率。這反映了公司營業收入的顯著增加。與醫療保健行業的其他公司相比，該公司的增長率高於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> OrthoPediatrics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-19.22%,</strong> the company may encounter challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> OrthoPediatrics 的淨利潤率低於行業標準，表明在實現強勁盈利能力方面存在困難。淨利潤率為 <strong>-19.22%</strong>，公司可能在有效控制成本方面面臨挑戰。</p>
</div><p><strong>Return on Equity (ROE):</strong> OrthoPediatrics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-3.34%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> OrthoPediatrics 的 ROE 低於行業平均水平，表明在最大化股本回報方面存在挑戰。ROE 為 <strong>-3.34%</strong>，公司可能在實現最佳財務表現方面面臨障礙。</p>
</div><p><strong>Return on Assets (ROA):</strong> OrthoPediatrics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.36%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> OrthoPediatrics 的 ROA 低於行業標準，表明在有效利用資產方面存在困難。ROA 為 <strong>-2.36%</strong>，公司可能在從其資產中獲得令人滿意的回報方面面臨挑戰。</p>
</div><p><strong>Debt Management:</strong> OrthoPediatrics's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.28</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> OrthoPediatrics 的債務與股本比率低於行業平均水平。比率為 <strong>0.28</strong>，公司較少依賴債務融資，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析師評級的相關性</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>評級來自分析師，或在銀行和金融系統內的專家，他們為特定股票或定義的行業報告（通常每季度一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以做出決策。</p>
</div><p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<div class="lb-trans"><p>分析師可以通過納入增長預估、收益和收入等指標的預測來增強他們的評估，為投資者提供額外的指導。重要的是要承認，儘管分析師在股票和行業方面是專家，但他們也是人，在提供見解時會表達自己的觀點。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

超越數字：5 位分析師討論 Orthopediatrics 的股票